# BNT211-01 (NCT04503278)

> A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

No report yet. It can be ordered.

- Drugs tested: CLDN6 CAR-T plus CLDN6 RNA-LPX; CLDN6 CAR-T
- Indication: CLDN6-positive relapsed or refractory advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04503278
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: BioNTech Cell & Gene Therapies GmbH
- Conditions: Solid Tumor
- Interventions: CLDN6 CAR-T; CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
- Enrollment: 214
- Primary outcome: Occurrence of treatment-emergent adverse events (TEAEs) including ≥ Grade 3, serious, fatal TEAEs by relationship
- Primary outcome: Occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) due to TEAEs
- Primary outcome: Occurrence of dose-limiting toxicity (DLT) during the DLT evaluation period

## Indexed commentary on BNT211-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=bnt211-01-nct04503278